Spectral Medical (TSE:EDT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Spectral Medical Inc. reported robust enrollment in the Tigris trial for its Polymyxin B Hemoperfusion treatment for septic shock, with completion expected by the end of 2024. Additionally, the company anticipates a positive impact from the Vantive-Carlyle Group transaction on the commercialization of its products.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
